{"groups":[{"description":"Participants received 3 cycles of oral solution of Xevinapant at a dose of 200 milligrams per day (mg/day) once daily from Day 1 to 14, per 3-week cycle in combination with 66 Gray (Gy) of intensity modulated radiation therapy (IMRT) in 33 fractions, 2 Gy/fraction, 5 days/week followed by 3 cycles of monotherapy of Xevinapant at a dose of 200 mg/day from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).","id":"FG000","title":"Xevinapant + IMRT"},{"description":"Participants received 3 cycles of oral solution of placebo matched to Xevinapant once daily from Day 1 to 14 per 3-week cycle in combination with with 66 Gray (Gy) of intensity modulated radiation therapy (IMRT) in 33 fractions, 2 Gy/fraction, 5 days/week followed by 3 cycles of monotherapy of placebo matched to Xevinapant from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).","id":"FG001","title":"Placebo + IMRT"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"14"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"}],"type":"Other Reasons"},{"reasons":[{"groupId":"FG000","numSubjects":"65"},{"groupId":"FG001","numSubjects":"66"}],"type":"Sponsor Premature Discontinuation Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"1"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"81"},{"groupId":"FG001","numSubjects":"85"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"82"},{"groupId":"FG001","numSubjects":"83"}],"comment":"SAF included all participants, who were administered any dose of any study intervention. Participants who were randomized to Placebo + IMRT but who were incorrectly administered any dose of Xevinapant were analyzed in the Xevinapant + IMRT group.","type":"Safety Analysis Set (SAF)"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"81"},{"groupId":"FG001","numSubjects":"85"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}